Jiangxi Provincial People's Hospital
江西省人民医院
Listed for 15 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Jiangxi Provincial People's Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Lung cancer肺癌19 papers led1 open trial led
- Glioma胶质瘤21 papers led
- Osteosarcoma骨肉瘤8 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤1 paper led
- Ewing sarcoma尤文肉瘤2 papers led
- Haemophilia A血友病 A0 papers led
- Myasthenia gravis重症肌无力2 papers led
- Coronary heart disease冠心病11 papers led
- Congenital heart disease先天性心脏病3 papers led
- Takayasu arteritis大动脉炎1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症14 papers led
- IgA nephropathyIgA 肾病0 papers led
- Osteogenesis imperfecta成骨不全症1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Lung cancer
肺癌Led 19 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.08%.
4 hospitals in Nanchang for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingXingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06848426
Age 18 years to 75 years (registered criteria)
Led by Jiangxi Provincial People's HospitalNanchang
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led19
- Dual-layer spectral detector CT quantitative parameters and radiomics for predicting spread through air spaces of lung adenocarcinoma: a dual-center study.
- UBE2N inhibition abrogates cancer chemoresistance and metastasis in lung adenocarcinoma.
- Predictive models of epidermal growth factor receptor mutation in lung adenocarcinoma using PET/CT-based radiomics features.
- Lymph node ratio emerges as a pivotal prognostic determinant for cancer-specific survival amidst individuals diagnosed with stage N1 and N2 non-small cell lung carcinoma: A population-based retrospective cohort study.
- Rapid differentiation of patients with lung cancers from benign lung nodule based on dried serum Fourier-transform infrared spectroscopy combined with machine learning algorithms.
- Machine learning identifies exosome related gene signatures for early prediction of non-small cell lung cancer.
- p32/OPA1 axis-mediated mitochondrial dynamics contributes to cisplatin resistance in non-small cell lung cancer.
- Inhibition of JNK/STAT3/NF-KB pathway-mediated migration and clonal formation of lung adenocarcinoma A549 cells by daphnetin.
- Early diagnostic value of ECT whole-body bone imaging combined with PINP and β-CTX for bone metastasis of lung cancer.
- Clinical Presentations and Intense FDG-avidity in Pulmonary Angiomatoid Fibrous Histiocytoma with Potential Diagnostic Pitfalls: A Case Report and Literature Review.
- Application Potential of Radiomics based on the Unenhanced CT Image for the Identification of Benign or Malignant Pulmonary Nodules.
- Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
- Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
- Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction.
- Comparison of serum from lung cancer patients and from patients with benign lung nodule using FTIR spectroscopy.
- Identification of a m6A-related ferroptosis signature as a potential predictive biomarker for lung adenocarcinoma.
- Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
- Computer-aided diagnosis system versus conventional reading system in low-dose (< 2 mSv) computed tomography: comparative study for patients at risk of lung cancer.
- Heat shock protein B8 promotes proliferation and migration in lung adenocarcinoma A549 cells by maintaining mitochondrial function.
All its trials on ClinicalTrials.gov, any status3
- Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Biomarkers for Diagnosis of Lung Cancer
Cancer
Glioma
胶质瘤Led 21 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Nanchang for glioma187 hospitals in China for glioma
No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led21
- Atom engineering for optimized photosensitizer performance in glioma photothermal and photodynamic therapy.
- Recent advances in the study of cuproptosis in gliomas.
- Integrative bulk and single-cell transcriptomic profiling identifies core gene networks and potential therapeutic targets in glioma.
- Integrating single-cell RNA-Seq and machine learning to dissect a novel Palmitoylation-related prognostic signature of glioblastoma.
- SIRT5-mediated BCAT1 desuccinylation and stabilization leads to ferroptosis insensitivity and promotes cell proliferation in glioma.
- Elevated HSPB1 Expression Is Associated with a Poor Prognosis in Glioblastoma Multiforme Patients.
- Targeted inhibition of branched-chain amino acid metabolism drives apoptosis of glioblastoma by facilitating ubiquitin degradation of Mfn2 and oxidative stress.
- CHIP-mediated ubiquitin degradation of BCAT1 regulates glioma cell proliferation and temozolomide sensitivity.
- The m6A reader HNRNPC promotes glioma progression by enhancing the stability of IRAK1 mRNA through the MAPK pathway.
- Automatic segmentation of brain glioma based on XY-Net.
- Bilateral thalamic and brainstem anaplastic astrocytoma: A case report.
- Depleting ANTXR1 suppresses glioma growth via deactivating PI3K/AKT pathway.
- Platycodin D suppresses proliferation, migration, and invasion of human glioblastoma cells through regulation of Skp2.
- Effect of lentinan on proliferation and apoptosis of human astrocytoma U251 cells.
- Identification of Potential Biomarkers of Platelet RNA in Glioblastoma by Bioinformatics Analysis.
- Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
- Cinnamaldehyde Downregulation of Sept9 Inhibits Glioma Progression through Suppressing Hif-1α via the Pi3k/Akt Signaling Pathway.
- High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma.
- Application of Enhanced T1WI of MRI Radiomics in Glioma Grading.
- LncRNA FEZF1-AS1 aggravates cell proliferation and migration in glioblastoma.
- Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway.
Cancer
Osteosarcoma
骨肉瘤Led 8 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Nanchang for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Elevated KIF2C Expression Drives Osteosarcoma Progression by Modulating the Wnt/β-Catenin Signaling Pathway and Contributing to an Immunosuppressive Tumor Microenvironment.
- AGPAT3 Regulates Immune Microenvironment in Osteosarcoma via Lysophosphatidic Acid Metabolism.
- Osteoblast-derived exosomes promote osteogenic differentiation of osteosarcoma cells via URG4/Wnt signaling pathway.
- The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma.
- Prognostic value of PRR11 and immune cell infiltration in Ewing sarcoma.
- FAM60A promotes osteosarcoma development and progression.
- The prognostic value of autophagy related genes with potential protective function in Ewing sarcoma.
- Case Report: Hyperplastic Callus of the Femur Mimicking Osteosarcoma in Osteogenesis Imperfecta Type V.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Nanchang for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Nanchang for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Ewing sarcoma
尤文肉瘤Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Nanchang for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Nanchang for haemophilia A132 hospitals in China for haemophilia A
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06833983
Age 18 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
- RecruitingOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Phase
- Phase 3
- Started
- 2021-11
- Posted
- Registry
- NCT05145127
Age 1 year to 74 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status15
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
Other diseases
Myasthenia gravis
重症肌无力Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Nanchang for myasthenia gravis89 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06447597
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status3
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
Other diseases
Coronary heart disease
冠心病Led 11 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Nanchang for coronary heart disease231 hospitals in China for coronary heart disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingOptimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Phase
- N/A
- Started
- 2021-09
- Posted
- Registry
- NCT04995159
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Anomalous Intercoronary Communication in the Setting of Chronic Left Circumflex Occlusion.
- The sentinels of coronary artery disease: heterogeneous monocytes.
- Prognostic value of geriatric nutritional risk index in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
- Therapeutic mechanism and key active ingredients of Yinxing Mihuan Oral Solution in coronary heart disease comorbidity with anxiety: A network pharmacology and molecular docking approach.
- The active pulling technique to solve microcatheter-uncrossable lesions in retrograde chronic total occlusion percutaneous coronary intervention.
- Diagnostic efficacy of the optical flow ratio in patients with coronary heart disease: A meta-analysis.
- Influence of enhanced external counterpulsation on endothelial function: a meta-analysis of randomized controlled trials.
- Clinical Efficacy of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Coronary Heart Disease Patients with SYNTAX Score ≥33 and Euro Score ≥6: A Single-Center Retrospective Analysis.
- Fasudil on Myocardial Injury in Rats with Myocardial Ischemia and Reperfusion through Rho-ROCK Signal Pathway.
- The potential function of SP1 and CPPED1 in restenosis after percutaneous coronary intervention.
- A Novel Clinical Scoring Model for Interventional Therapy in Chronic Total Occlusion of the Coronary Artery.
Other diseases
Congenital heart disease
先天性心脏病Led 3 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Nanchang for congenital heart disease207 hospitals in China for congenital heart disease
No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led3
- Anomalous Intercoronary Communication in the Setting of Chronic Left Circumflex Occlusion.
- Stentless balloon angioplasty preserving growth in adolescent congenital focal abdominal aortic coarctation: a case report.
- Exploring new frontiers: a rare case of catheter ablation for persistent atrial fibrillation in a patient with cor triatriatum sinister guided by intracardiac echocardiography.
Other diseases
Takayasu arteritis
大动脉炎Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Nanchang for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Nanchang for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 14 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Nanchang for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led14
- Preliminary Analysis of Potentially Overlapping Differentially Expressed Proteins in Both the Spinal Cord and Brain of SOD1 G93A Mice.
- The Current Potential Pathogenesis of Amyotrophic Lateral Sclerosis.
- Overview of nomenclature and diagnosis of amyotrophic lateral sclerosis.
- Current potential diagnostic biomarkers of amyotrophic lateral sclerosis.
- Current potential pathogenic mechanisms of copper-zinc superoxide dismutase 1 (SOD1) in amyotrophic lateral sclerosis.
- In Vitro Models of Amyotrophic Lateral Sclerosis.
- Potential effects of brain lipid binding protein in the pathogenesis of amyotrophic lateral sclerosis.
- The pathogenesis of amyotrophic lateral sclerosis: Mitochondrial dysfunction, protein misfolding and epigenetics.
- Nerve Growth Factor is a Potential Treated Target in Tg(SOD1*G93A)1Gur Mice.
- Identification of Molecular Correlations Between DHRS4 and Progressive Neurodegeneration in Amyotrophic Lateral Sclerosis By Gene Co-Expression Network Analysis.
- Melatonin Induces Autophagy in Amyotrophic Lateral Sclerosis Mice via Upregulation of SIRT1.
- Distribution Features and Potential Effects of Serotonin in the Cerebrum of SOD1 G93A Transgenic Mice.
- Perilipin 4 Protein: an Impending Target for Amyotrophic Lateral Sclerosis.
- Preclinical studies of mesenchymal stem cells transplantation in amyotrophic lateral sclerosis: a systemic review and metaanalysis.
Earlier papers (2016–2020)3
- Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1G93A Mice.
- All-Trans Retinoic Acid Exerts Neuroprotective Effects in Amyotrophic Lateral Sclerosis-Like Tg (SOD1*G93A)1Gur Mice.
- Altered Features of Vimentin-containing Cells in Cerebrum of Tg(SOD1*G93A)1Gur Mice: A Preliminary Study on Cerebrum Endogenous Neural Precursor Cells in Amyotrophic Lateral Sclerosis.
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Nanchang for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
Osteogenesis imperfecta
成骨不全症Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Nanchang for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
江西省人民医院
Jiangxi Provincial People's Hospital
南昌
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.